Licensing Fees: A Historical Overview
Licensing fees have been an integral part of the genetics industry for centuries. The practice of licensing allows companies to protect their intellectual property and earn revenues from their discoveries, while enabling other businesses to use these inventions for a fee.
The idea of licensing can be traced back to medieval times when European monarchs granted exclusive rights to certain tradespeople, such as bakers or brewers. In the early days of genetics research, however, there were no formal mechanisms in place for protecting new discoveries.
It wasn’t until the 20th century that modern patent law emerged. The United States Patent and Trademark Office (USPTO) was established in 1790 but it wasn’t until the late 1800s that biological materials were included under patent protection. In 1930, Congress passed the Plant Patent Act which extended patent eligibility to plants created through asexual reproduction methods like grafting or cutting.
In 1980, the US Supreme Court ruled on Diamond v. Chakrabarty which upheld a patent on a new genetically modified bacterium developed by Ananda Mohan Chakrabarty at General Electric’s Research and Development Center in Schenectady, New York. This decision paved the way for biotechnology patents covering genetic material and organisms derived from them.
Since then, licensing fees have become standard practice in all areas of genetics research including gene editing technologies like CRISPR/Cas9 and gene therapies such as CAR-T cell therapy.
One notable example is Myriad Genetics who patented two genes associated with breast cancer – BRCA1 and BRCA2 – in 1997. The company charged thousands of dollars for its diagnostic test that detected mutations in these genes which could indicate an increased risk of developing breast or ovarian cancer. However, after years of controversy and legal battles over whether human genes should be eligible for patents at all, the Supreme Court finally ruled against Myriad in 2013 and declared that naturally occurring human genes cannot be patented.
Another example is the case of the CRISPR-Cas9 gene-editing technology which was first developed by Jennifer Doudna and Emmanuelle Charpentier. The Broad Institute, MIT, Harvard University, UC Berkeley and others have all been involved in legal battles over patent rights to this technology since its discovery. In September 2018, a federal appeals court ruled in favor of the Broad Institute stating that they had made “fundamental” discoveries about how CRISPR works.
While licensing fees can provide a steady source of income for companies who hold patents on genetic material or technologies, they also have their downsides. For one thing, licensing fees can make genetic testing unaffordable for patients who may need it most. Furthermore, some argue that overly broad patents can stifle innovation by preventing other researchers from building upon existing discoveries.
Despite these concerns, however, licensing fees remain an important part of the genetics industry today. Companies like Illumina – who produce DNA sequencing machines used extensively in scientific research – earn significant revenues from selling licenses to use their patented technologies.
In conclusion, licensing fees have been around as long as people have been creating things worth protecting. In genetics research specifically though we’ve seen a transformation from no formal mechanisms at all to now involving thousands of dollars and key legal battles surrounding new discoveries. It remains imperative that we continue to balance both protection for those developing these new technologies with accessibility for those needing them most so that medical advancements continue to reach everyone regardless of socioeconomic status or background.